Stockpolly
Search
OBIO · NASDAQ · Biotechnology

Orchestra BioMed (OBIO)

Develops partnership-enabled device therapies for hypertension and artery disease.

$4.95
At close+0.05 (+1.02%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0011101113100
Cost of revenue000000000000
Gross profit0011101113100
151315181717202021242222
Research & development999111211131414171617
646666667766
General & administrative000000000006
Other expenses000000000000
Operating income−15−12−14−17−16−17−19−19−207−22−22
10111100−1−11−1
Interest income111111000000
Interest expense000000001110
Other non-operating income00−1−1−1−10010−21
Income before tax−13−13−13−16−15−16−19−19−216−21−24
Net income from continuing operations−13−13−13−16−15−16−19−19−216−21−24
Net income−13−13−13−16−15−16−19−19−216−21−24
EPS, basic−$0.38−$0.36−$0.38−$0.45−$0.41−$0.42−$0.49−$0.50−$0.40$0.12−$0.33−$0.38
EPS, diluted−$0.38−$0.36−$0.38−$0.45−$0.41−$0.42−$0.49−$0.50−$0.40$0.12−$0.33−$0.38
Weighted average shares, basic353636363838383852506364
Weighted average shares, diluted353636363838383852506364
EBITDA−14−13−13−16−15−16−19−19−217−20−24
Depreciation & amortization000000000000
EBIT−15−13−13−16−15−16−19−19−217−20−24